Arbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Decreased Their Shorts By 31.2%

Arbutus Biopharma Corporation (NASDAQ:ABUS) Corporate Logo

Arbutus Biopharma Corporation (NASDAQ:ABUS) had a decrease of its shares shorted by 31.2%. FINRA published in December ABUS’s total 1.68 million shares shorted. The 2.45M previous shares are down with 31.2%. 9 days will cost ABUS with 181,100 average volume to restore its former position. Arbutus Biopharma Corporation’s shares shorted float is 5.4%.

Ticker’s shares touched $4.4 during the last trading session after 3.93% change.Currently Arbutus Biopharma Corporation is uptrending after 119.54% change in last December 8, 2017. ABUS has also 120,184 shares volume. ABUS outperformed the S&P500 by 103.92%.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States.The company has $244.20 million market cap. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).Currently it has negative earnings. The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

For more Arbutus Biopharma Corporation (NASDAQ:ABUS) news released recently go to:,,, or The titles are as follows: “The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss – Benzinga” released on August 10, 2018, “18 Stocks Moving In Friday’s Pre-Market Session – Benzinga” on July 06, 2018, “Arbutus down 16% after Q2 report – Seeking Alpha” with a publish date: August 03, 2018, “Risk-Adjusted Net Present Value For Arbutus Biopharma Corp – Seeking Alpha” and the last “Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: August 03, 2018.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.